Good afternoon, everybody. I'm Chris Schott at JPMorgan and it's my pleasure to be hosting this fireside chat today with Dave Ricks, Chairman and CEO of Eli Lilly. It's been a tremendous few years ...

Eli Lilly (NYSE:LLY) CEO Dave Ricks said Monday that the company's GLP-1 weight-loss pill orforglipron could receive FDA approval as soon as early 2026. In an interview with Bloomberg TV ...

We recently published a list of Jim Cramer Discussed These 18 Stocks As Inflation Dropped. In this article, we are going to ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Regarding the guidance approach, the CEO noted, "The scale of this business ... the 3Q results and guidance update." Price Action: LLY stock is up 0.59% at $749.28 at the last check on Wednesday.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

Madrigal Pharmaceuticals Inc. (MDGL) is our top conservative biotech recommendation for 2025. The company is in the sweet spot and de-risked with the first FDA-approved drug for chronic liver ...

Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A. Ricks, Lilly chair and CEO, will participate in a fireside chat on ...

Also Read: Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall Omvoh works ... of additional treatment (two ...

CEO Elon Musk over his purchase of Twitter; and Eli Lilly (LLY) stock is in focus after plunging yesterday on lower revenue projections. Here's what investors need to know today. 1. US Stock Futures ...